« Return to News | Drug Sponsors

Bionovo struggles to gain funding

Monday, March 12, 2012 03:40 PM

Bionovo, a pharmaceutical company focused on women's health and cancer, said it needs to obtain substantial additional funding to achieve its objectives of internally developing drugs.

The company has already reduced its workforce by over 90%. The remaining management of Bionovo will receive reduced cash compensation until either adequate financing can be obtained or the company is sold. 

On March 12, Bionovo entered into a securities purchase agreement with investors to purchase an aggregate of 14,231,696 shares of common stock for approximately $426,951.

Additionally, each investor will receive a warrant exercisable into shares of Bionovo common stock. The warrants shall be exercisable into an aggregate of 11,485,844 shares of common stock at an exercise price of $0.03 per share and expire on March 30. If the warrants are exercised in full for cash, Bionovo will receive an approximate additional $344,575.

If sufficient additional funds are not received in the near term, the company may not be able to execute its business plan and may need to further curtail or cease operations.

Bionovo’s management and board of directors are continuing to explore strategic options for the company and are currently reviewing the status of the ongoing clinical trial for Menerba.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.